^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PB103
i
Other names: PB103
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Chongqing Precision Biotech
Drug class:
NK cell stimulant
Related drugs:
10ms
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov)
P1/2, N=24, Recruiting, Precision Biotech Taiwan Corp. | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2027
Trial completion date • Trial primary completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
PB103
2years
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov)
P1/2, N=24, Recruiting, Precision Biotech Taiwan Corp. | Trial primary completion date: Jun 2022 --> Dec 2024
Trial primary completion date • Combination therapy
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
PB103
Share via
